Deka Biosciences (“Deka”), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.
The Oklahoman: NBA star Russell Westbrook adds pharmaceutical startup to growing investments in OKC
Westbrook, who played for the Oklahoma City Thunder for several years, has made multiple investments in the city since leaving the team.